Coherus Oncology

Executive Summary

Coherus Oncology is a commercial-stage biopharmaceutical company dedicated to developing and commercializing next-generation combination therapies for cancer. Based in Redwood City, California, the company leverages its expertise in biologics and biosimilars to address significant unmet needs in oncology. Coherus’s lead product, Udenyca (pegfilgrastim-cbqv), a biosimilar to Neulasta, provides a steady revenue stream and supports its broader pipeline. The company is advancing its innovative immuno-oncology candidate, toripalimab, a PD-1 inhibitor licensed from Junshi Biosciences, which is being evaluated in multiple combination trials for cancers such as non-small cell lung cancer and hepatocellular carcinoma. Coherus also has a robust biosimilar pipeline targeting key oncology supportive care agents. With a commercial infrastructure in place and a focus on cost-effective therapies, Coherus is well-positioned to capture market share in the growing biosimilar and immuno-oncology segments. However, the company faces intense competition from established players and biosimilar rivals, and its valuation remains private, limiting transparency. Near-term growth hinges on clinical data readouts, regulatory milestones, and successful commercialization of toripalimab upon potential approval.

Upcoming Catalysts (preview)

• Q3 2026FDA Decision on Toripalimab for Nasopharyngeal Carcinoma65% success
• Q4 2026Top-Line Data from Phase 2 Toripalimab + Chemotherapy in First-Line NSCLC55% success
• Q1 2027New Biosimilar Filing (Pegfilgrastim or Bevacizumab Variant)80% success